Theaflavin-3-gallate

Theaflavin-3-gallate (TF-2b) is a polyphenolic flavanol formed during black tea fermentation through the oxidative condensation of catechins, specifically epigallocatechin and epicatechin gallate. It exerts biological activity primarily as a prooxidant, inducing reactive oxygen species (ROS) generation and apoptosis in cancer cell lines while modulating inflammatory signaling pathways.

Origin & History

Theaflavin-3-gallate is a polyphenolic flavonoid found abundantly in black tea (Camellia sinensis) and produced during the fermentation process of tea leaves. It belongs to the class of catechin gallates with a molecular formula of C₃₆H₂₈O₁₆ and molecular weight of 716.6 g/mol.

Historical & Cultural Context

The research dossier does not provide information about historical or traditional use of theaflavin-3-gallate specifically. While it is a major component of black tea, no traditional medicine applications are documented in the available sources.

Health Benefits

• May possess chemopreventive activity based on preliminary research (evidence quality: preliminary)
• Has been studied as a potential cancer-fighting compound when combined with cisplatin against ovarian cancer cells (evidence quality: preliminary in-vitro only)
• Acts as a prooxidant that induces oxidative stress in carcinoma cells (evidence quality: preliminary mechanistic data)
• Reported to have antioxidant properties as part of the theaflavin family (evidence quality: preliminary)
• May have anti-pathogenic properties according to preliminary reports (evidence quality: preliminary)

How It Works

Theaflavin-3-gallate functions as a prooxidant by generating intracellular reactive oxygen species (ROS), which triggers mitochondrial-mediated apoptosis through cytochrome c release and caspase-3/9 activation. It has been shown to inhibit NF-κB signaling and downregulate anti-apoptotic proteins such as Bcl-2 and Bcl-xL in cancer cell models. When combined with cisplatin in ovarian cancer cell studies, it appears to enhance cytotoxic efficacy, potentially by disrupting redox homeostasis and sensitizing cells to platinum-based DNA damage.

Scientific Research

The research dossier does not contain specific human clinical trials, randomized controlled trials, or meta-analyses with PMIDs for theaflavin-3-gallate. Current evidence is limited to preliminary in-vitro studies, including research on its combination with cisplatin against ovarian cancer cells, though specific study details and outcomes are not provided in the available sources.

Clinical Summary

Research on theaflavin-3-gallate remains almost entirely preclinical, with no published human clinical trials evaluating its isolated effects as of current literature. In vitro studies using ovarian cancer cell lines (e.g., SKOV-3) have demonstrated synergistic cytotoxicity when TF-2b is combined with cisplatin, reducing cell viability at concentrations in the low micromolar range. Animal model studies have suggested chemopreventive potential against chemically induced carcinogenesis, though doses and bioavailability have not been validated in humans. The overall evidence is preliminary and insufficient to support clinical recommendations.

Nutritional Profile

Theaflavin-3-gallate (TF-2a) is a pure bioactive polyphenolic compound, not a whole food, and therefore has no macronutrient, fiber, or conventional micronutrient profile. Molecular formula: C43H34O20; molecular weight: approximately 882.72 g/mol. It is one of four major theaflavin monomers found in black tea, typically present at concentrations of 0.5–2.0 mg per gram of dry black tea leaf, representing a minor fraction of total theaflavins (which collectively comprise 0.3–1.8% of black tea dry weight). As a polyphenolic catechin oxidation product, it contains a benzotropolone (theaflavin) core esterified with a gallic acid moiety at the 3-position. It is structurally distinct from theaflavin (TF1), theaflavin-3'-gallate (TF-2b), and theaflavin-3,3'-digallate (TF3). Bioavailability is characteristically poor for this compound class: oral bioavailability is estimated at less than 5% in humans due to limited intestinal absorption, extensive first-pass metabolism, and colonic microbial degradation into smaller phenolic metabolites (e.g., gallic acid, pyrogallol, and various hydroxyphenylpropionic acids). Protein binding in plasma is high (>80%). No caloric, fat, carbohydrate, or vitamin content is attributable to this isolated compound. Studied primarily in purified or semi-purified form in research contexts, not as a dietary supplement with established dosing.

Preparation & Dosage

No clinically studied dosage ranges are available in the research for theaflavin-3-gallate in any form (extract, powder, or standardized preparations). Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other theaflavins, EGCG, green tea catechins, quercetin, curcumin

Safety & Interactions

No formal human safety trials have been conducted on isolated theaflavin-3-gallate supplementation, making a comprehensive side effect profile unavailable. Because it acts as a prooxidant, concurrent use with antioxidant supplements such as vitamin C or vitamin E could theoretically antagonize its proposed mechanisms, though this has not been clinically confirmed. Its structural similarity to other gallated catechins raises a plausible concern for interaction with anticoagulants like warfarin, as well as iron chelation that could impair non-heme iron absorption. Pregnant and breastfeeding individuals should avoid isolated supplementation due to the complete absence of safety data in these populations.